• Tariq Mahmood.
• Leeds and York Partnership NHS Foundation Trust, 2150 Century Way, Thorpe Park Gardens, Leeds LS15 8ZB, UK.
• Br. Med. Bull. 2020 Oct 14; 135 (1): 23-27.

IntroductionThe dearth of biomarkers limits the precision of our research into pathogenesis of psychiatric disorders and has slowed down the development of new drugs. In clinical practice, it undermines the validity of psychiatric diagnoses and hampers the delivery of personalized treatment.Sources Of DataThe data quoted in this paper are gathered from a range of sources encompassing scientific and journalistic both in print and electronic.Areas Of AgreementAvailability of clinically useful biomarkers will improve the prognosis and outcome of psychiatric patients by helping in early diagnosis and delivery of individualized treatment.Areas Of ControversyThe cross-sectional and longitudinal observation of psychopathology is the bedrock of current clinical practice. Are psychiatric biomarkers advanced enough to supplant it?Growing PointsThe need for biomarkers of psychiatric disorders has become more acute with the advent of new treatments which require precision and an individualized approach.Areas Timely For Developing ResearchIdentification and deployment of intermediate phenotypes in classification, research and clinical practice of psychiatry.© The Author(s) 2020. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

11 keywords...

hide…